John E. Wehrli, Ph.D., M.B.A.

Experience: Strategic Alliances, Partnering Deals, and Collaborations: Two winners of the Pantheon Award for outstanding partnering deal of the year.; A series of deals for seminal cancer drug Zelboraf, winner of the Pantheon Award for outstanding therapeutic product of the year.; Financial Times 4th most innovative strategic transaction of 2012 in its Innovative Lawyers Report.; 42 partnering deals/strategic alliances each valued over $100 million that totaled $50 billion.; 84 multimillion-dollar strategic alliances, corporate partnering and collaboration agreements.; Over 650 life science intellectual property transactions.; Numerous strategic Joint Ventures, Spin-Outs and Co-Promotion Agreements.; Numerous headline strategic alliances in HCV, cancer, autoimmune disease, and other indications including: Aspect/Novo-Nordisk: $2.7 billion deal for bioprinted tissue therapeutics in diabetes and obesity.; Arcellx/Kite-Gilead: $4.2 billion deal for CART-ddBCMA for relapsed or refractory multiple myeloma.; Regor/Eli Lilly: $1.6 billion metabolic disorder pre-clinical collaboration for a Chinese client.; Alios/Vertex: $1.5 billion+ HCV nucleoside/nucleotide pro-drug global collaboration.; Intermune/Roche: $530 million HCV Protease inhibitor (Danoprevir) global collaboration.; Tacere/Pfizer: $145 million HCV expressed RNAi global collaboration.; Plexxikon/Roche: $706 million Zelboraf (vemurafenib) BRAF cancer global collaboration.; CG Oncology/Kissei: $140 million global cancer collaboration.; Chiasma/Roche: $600 million oral somatostatin analog Octreolin for acromegaly and neuroendocrine tumors global collaboration.; Novacea: /; Schhering-Plough: $500+ million VDR (Asentar) prostate cancer global collaboration.; Geron/Merck: telomerase vaccine cancer global collaboration.; Plexxikon/Wyeth: $464 million (PPAR) Type II diabetes global collaboration.; Bayhill/Genentech-Roche: $350+ million Type I diabetes global collaboration.; Kythera/Bayer: $373 million submental fat reduction global collaboration.; Plexxikon: /; Roche: $335 million RAF kinase polycystic kidney disease global collaboration.; Renovis/Pfizer: $187 million vanilloid receptor (VR1) pain global collaboration.; Plexxikon/Servier: $112 million rennin inhibitor cardiovascular global collaboration.; Coherus Biosciences: in a series of interlocking transactions selected by Financial Times as one of the 4 most innovative strategic transactions of 2012.; Allergan/ GlaxoSmithKline: co-promotion agreement for IMITREX STATdose and AMERGE for the treatment of headache in the United States.; Allergan/ GlaxoSmithKline: global strategic alliance covering the development and promotion of BOTOX in Japan and China.; Intuitive Surgical/Adachi/Johnson & Johnson Japan: collaboration for its da Vinci surgical robotic platform.; CV Therapeutics/Solvay Pharmaceuticals: co-promotion agreement for ACEON (perindopril erbumine) tablets, an angiotensin converting enzyme (ACE) inhibitor for hypertension.; Accuray: in its spin-out transaction with; CyberHeart: for the application of its CyberKnife sterotactic radiosurgery technology into the cardiovascular field.; Over 90% of major deals are cross-border or involve global rights.; Mergers and Acquisitions: Over 75 life science M&A transactions valued at over $61 billion including asset purchases, tender offers, stock mergers, forced divestitures, and leveraged buyouts, including: WuXi: in the sale of its Wuxi AppTech's U.S. medical device testing operations to; NAMSA: .; WuXi: in the sale of its Wuxi AppTec's Advanced Therapies unit U.S. and U.K. operations to; Altaris: .; Eli Lilly: in its acquisition of; ImClone: for $6.5 billion.; Plexxikon: in its acquisition by; Daichi-Sankyo: for $935 million.; Eli Lilly: in its acquisition of; Johnson & Johnson's: animal health business.; Eli Lilly: in its acquisition of a portfolio of; Pfizer's: European animal health products.; Eli Lilly: in its acquisition of; Alnara Pharmaceuticals: .; Santarus: in its acquisition by; Salix Pharmaceuticals: for $2.6 billion.; A; Pharma-Pharma: acquisition for $7 billion.; A pharmaceutical subsidiary acquisition for $1 billion.; An Animal Health acquisition for $1.6 billion.; Watson Pharmaceuticals: in its acquisition of; Arrow Pharmaceuticals: for $1.75 billion.; Cougar Biotechnology: in its acquisition by; Johnson & Johnson: for $1 billion.; A; Pharma-Pharma Division: acquisition for $8 billion.; A medical device leveraged buy-out for $4 billion.; A medical device acquisition for $2.8 billion.; Ulthera: in its acquisition by; Merz: for $600 million.; Alios BioPharma: in its acquisition by; Johnson & Johnson: for $1.75 billion.; Visiogen: in its acquisition by; Abbott: for $400 million.; Novacea: in its merger with; Transcept Pharmaceuticals: .; Raven: in its merger with; Vaxgen: .; Renovis: in its acquisition by; Evotec: for $151 million.; Integra Life Sciences: in its acquisition of; Kinetikos Medical: for $40 million.; Vivant: in its acquisition by; Tyco: for $101 million.; Takeda: in its acquisition of; Syrrx: for $270 million.; Coalescent Surgical: in its acquisition by; Medtronic: for $54 million.; Capital Markets and Venture Capital IP Due Diligence: IP Due Diligence counsel to over 300 life science corporate transactions.; IP Due Diligence counsel to over 170 life science public offerings that have raised over $22 billion in aggregate.; The above representations were handled by Dr. Wehrli prior to his joining Greenberg Traurig, LLP.; Asia: Dr. Wehrli has extensive experience in Asia: Representing many Asia based clients over the years including: Chengdu Kanghong (China); Chugai Pharmaceuticals (Japan); GPCR Therapeutics (Korea); HuyaBio (China); ICM (Korea); Kai Pharmaceuticals (Japan); Kyowa-Hakko (Japan); Mitsubishi (Japan); Nomura Securities (Japan); Olympus Medical Systems (Japan); Regor (China); ScinoPharm (Taiwan); Sumitomo Dianippon Pharma (Japan); Tianjin (China); Takeda Pharmaceuticals (Japan); Takeda Research Investments (Japan); WuXi (China); Zailab (China); Negotiating opposite many Asian companies on major deals, including: Adachi (Japan); Astellas (Japan); Changsan (China); Chugai Pharmaceuticals (Japan); Daiichi-Sankyo (Japan); Esia (Japan); Japan Tobacco (Japan); Kakken (Japan); Kirin (Japan); Kissei (Japan); Kwowa-Hakko (Japan); Otzuka (Japan); Sangamo Biosciences (Japan); Seikagaku (Japan); Taigen (Taiwan); Takeda (Japan); WuXi (China); Negotiating headline deals including: Allergan/ GlaxoSmithKline global strategic alliance covering the development and promotion of BOTOX in Japan and China.; CG Oncology/Kissei$140 million global cancer collaboration.; Intuitive Surgical/Adachi/Johnson & Johnson Japan collaboration for its da Vincisurgical robotic platform.; WuXi in the sale of its Wuxi AppTech's U.S. medical device testing operations to NAMSA.; WuXi in the sale of its Wuxi AppTec's Advanced Therapies unit U.S. and U.K. operations to Altaris.; Plexxikon in its acquisition by Daichi-Sankyo for $935 million.; Regor/Eli Lilly $1.6 billion metabolic disorder pre-clinical collaboration for a Chinese client.; Takeda in its acquisition of Syrrx for $270 million.; Europe: Dr. Wehrli has extensive experience in Europe: Representing many European clients over the years including: Boehringer-Ingelheim (Germany); Credit Suisse (Switzerland); Idorsia (Switzerland); Nycomed (Germany); Bio-orbit (UK); Linkgevity (UK); Nordic Capital (Sweeden); Deutsch Bank (Germany); Sanofi-Aventis (France); Negotiating opposite numerous European companies including: Alcon (Switzerland); AstraZenca (UK/Sweden); Bayer (Germany); B. Braun (Germany); BioNTech (Germany); Boehringer-Ingelheim (Germany); Evotek (Germany); Fresenius (Germany); Gemab (Denmark); GSK (UK); Lonza (Italy); Merck-AG (Germany); Novartis (Switzerland); Novo-Nordisk (Denmark); Philips (Netherlands); Roche (Switzerland); Servier (France); Siemens (Germany); Smith & Nephew (UK); Solvay (Belgium); UCB (Belgium); Negotiating headline deals including: Aspect/Novo-Nordisk $2.7 billion deal for bioprinted tissue therapeutics in diabetes and obesity.; Intermune/Roche $530 million HCV Protease inhibitor (Danoprevir) global collaboration.; Plexxikon/Roche $706 million Zelboraf (vemurafenib) BRAF cancer global collaboration.; Chiasma/Roche $600 million oral somatostatin analog Octreolin for acromegaly and neuroendocrine tumors global collaboration.; Plexxikon/Roche $335 million RAF kinase polycystic kidney disease global collaboration.; Kythera/Bayer $373 million submental fat reduction global collaboration.; Plexxikon/Servier $112 million rennin inhibitor cardiovascular global collaboration.; Allergan/ GlaxoSmithKline co-promotion agreement for IMITREX STATdose and AMERGE for the treatment of headache in the United States.; Renovis in its acquisition by Evotec for $151 million.; Pro Bono & Scholarly Practice: Having started his law firm career as a litigator, for over 30 years Dr. Wehrli has had a multi-award-winning, litigation-focused pro bono practice in criminal law and family law (including false confessions by children and adolescents), child-centered intimate partner domestic violence, and children's rights and protection (including guardianship and child custody cases), and currently focuses on child psychological abuse, including estrangement and alienation. Dr. Wehrli has argued over three dozen evidentiary bench trials and has been the attorney of record or supervisor of another over 150 domestic violence and child custody cases.; Dr. Wehrli is a member of several child-focused professional organizations including the American Professional Society on the Abuse of Children and the Parental Alienation Study Group, and is on the Advisory Council for National Family Justice. Dr. Wehrli was awarded an Angel Award by California Lawyer Magazine as one of the top 20 pro-bono lawyers in the state, the Advocate Award by the Pro-Bono Project of Silicon Valley, the Outstanding Service Award by the Legal Aid Society of San Diego, and was twice awarded the Distinguished Service Award by the San Diego Volunteer Lawyer Program. Dr. Wehrli was previously elected to the board of directors for the Pro Bono Project of Silicon Valley and the Legal Aid Society of San Diego and served as a chair of the pro bono committee for Latham & Watkins.; During his early litigation career, Dr. Wehrli focused on the evaluation, preparation, and direct and cross-examination of scientific experts under both Daubert trilogy and Frye standards, including preparation and evaluation of expert reports and tutorials, primarily in chemistry, molecular biology, pharmacology, computational mathematics, and statistics. Over the past decade, Dr. Wehrli has consulted on the evaluation of scientific evidence, experts, and expert reports in neuroscience, psychology, and psychiatry throughout the United States and Canada. Dr. Wehrli is currently Associate Editor and contributing author for the upcoming edition of Forensic Medicine, Psychiatry, and Psychology: A Handbook for Expert Litigators and Litigator's Experts. Dr. Wehrli also publishes and conducts collaborative interdisciplinary research and policy work in the fields of space law, AI law, law and psychology, mental health law, and law and neuroscience.; Professional Certifications: GTC Certified Expert, Machine Learning; GTC Certified Expert, AI; AI in Pharma & Biotech, Massachusetts Institute of Technology; Systems Biology, Ichan School of Medicine at Mount Sinai; Biomathematics, Bioinformatics, and Computational Biology, University of California, Santa Cruz; Mathematical and Computational Biostatistics (with Distinction), Johns Hopkins University; Complex and Nonlinear Computational Mathematics, Santa Fe Institute; Patents: Inventor: US 6,542,858. Pharmacokinetic-based drug design tool and method.; US 6,647,358. Pharmacokinetic-based drug design tool and method.; US 6,996,473. Method for screening and producing compound libraries.; US 20020061540. Method for screening and producing compound libraries.; US 20020010550. Pharmacokinetic-based drug design tool and method.; US 20020013662. Pharmacokinetic-based drug design tool and method.; US 20020035459. Pharmacokinetic-based drug design tool and method.; US 20010041964. Pharmacokinetic-based drug design tool and method.